The verdict
Our read at a glance.
Whether glepaglutide's late-stage short bowel syndrome data support its approval and use in that specific condition, separate from broad gut-repair claims.
- The signal
- Late-stage trials, including the EASE program, have tested glepaglutide for reducing the need for parenteral support in short bowel syndrome. As an investigational drug, its full evidence and regulatory status are still being established.
- The unknown
- Whether it offers a meaningful advantage over existing GLP-2 therapy, and its long-term safety, including the neoplasia concerns common to the GLP-2 class.
- Our read
- Another late-stage GLP-2 drug for short bowel syndrome, still investigational. Until approval and full data, glepaglutide should be read as investigational rather than established.
The mechanism
How it works.
Glepaglutide is a long-acting analog of glucagon-like peptide-2 (GLP-2), the hormone gut cells release after meals to maintain the intestinal lining. It activates the GLP-2 receptor on cells in the intestinal wall, which drives the lining to grow, raises local blood flow, and increases how much nutrient and fluid the bowel can absorb. In short bowel syndrome the aim is to enlarge that absorptive surface enough to reduce dependence on intravenous feeding, and it is engineered to last long enough for less frequent dosing than earlier GLP-2 drugs. It is still in late-stage trials and is not an approved product.
Safety & regulatory boundary
The consequential part.
Glepaglutide is investigational and not an approved product in general use during this period. GLP-2 analogs as a class raise concerns about promoting growth, including potential neoplasia and intestinal effects, which any approval would manage through monitoring. Research-labeled or compounded glepaglutide is not an approved product, and its development status does not support use outside trials.
What's next
What we're watching.
Regulatory decisions, published Phase 3 results, and long-term safety and neoplasia surveillance.
Context
Why this is discussed.
Glepaglutide is another leading next-generation GLP-2 analog, relevant to short bowel syndrome patients and the broader GLP-2 field.
The evidence base
20 cited references.
Registered trials8
ClinicalTrials.gov · PHASE3 · RECRUITING · 2026-02-11
ClinicalTrials.gov · PHASE3 · ENROLLING_BY_INVITATION · 2025-12-11
ClinicalTrials.gov · PHASE3 · ACTIVE_NOT_RECRUITING · 2021-06-16
ClinicalTrials.gov · PHASE3 · ACTIVE_NOT_RECRUITING · 2019-05-07
ClinicalTrials.gov · PHASE3 · COMPLETED · 2018-10-04
ClinicalTrials.gov · PHASE3 · COMPLETED · 2021-08-10
ClinicalTrials.gov · PHASE1 · COMPLETED · 2020-03-04
ClinicalTrials.gov · PHASE1 · COMPLETED · 2019-12-10
Indexed literature (PubMed)12
Jeppesen PB et al. · Gastroenterology · 2025
Sabra HK et al. · J Gastrointest Surg · 2024
Goldschmidt ML et al. · Expert Opin Pharmacother · 2024
Naimi RM et al. · JPEN J Parenter Enteral Nutr · 2023
Hyder A et al. · JGH Open · 2025
Hvistendahl MK et al. · JPEN J Parenter Enteral Nutr · 2022
Pironi L · Curr Opin Clin Nutr Metab Care · 2024
Hollanda Martins Da Rocha M et al. · Expert Opin Pharmacother · 2020
Bastas A et al. · Clin Nutr ESPEN · 2026
Agersnap MA et al. · Clin Drug Investig · 2022
Hvistendahl MK et al. · JPEN J Parenter Enteral Nutr · 2020
Frau T et al. · Expert Opin Emerg Drugs · 2024
Keep reading